(OA02) Circulating Tumor DNA Quantitation for Early Response Assessment of Immune Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer

Immune checkpoint inhibitors (ICIs) are commonly used for treatment of advanced stage non-small cell lung cancer (NSCLC) and numerous clinical studies are examining combinations of ICIs with radiotherapy (RT). Standard-of-care response assessment is CT imaging, which is typically performed no earlier than 2-3 months after treatment initiation due to delayed radiographic responses and occasional pseudoprogression. Improved methods of response assessment would be useful clinically and in trials combining ICIs and RT.

https://ift.tt/2HQLiWL